CVSA
Covista Inc.
Next earnings Aug 5, 2026 (after close) · consensus $1.92 EPS, $496M rev
Last earnings +1.5% on 2026-05-07
$127.53
▲ +2.71%$127.53▼ -0.39%
over 1Y
L $89.36EODHDH $154.45
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.7%
1W+6.9%
1M+4.1%
3M+11.3%
YTD+22.1%
1Y-0.4%
Buy
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 10 analysts
Strong Buy
Adtalem (CVSA) compounding nicely: 12.9% revenue growth, EPS +82%, deleveraging, and a buyback — still only 19.9x earnings.
Revenue $1.79B · FY2025
The read
Quality fundamentals and an attractive price line up (~84% below fair value) — the rarer case where both the business and the entry look good.
The numbers and the filing tell a coherent story of operational acceleration. Revenue grew 12.9% to $1.79B in FY2025 with all three segments contributing, while net income jumped 73.3% to $237M and diluted EPS surged 82.3% to $6.18. The MD&A is explicit that the earnings leverage came from a combination of top-line growth, lower interest expense (the $100M January 2025 Term Loan B prepayment is doing real work), reduced amortization of acquired intangibles, and smaller litigation reserves — partially offset by reinvestment in marketing, labor, and growth initiatives. Operating margin expanded to 19.1% and ROE reached 16.5%, both healthy for the for-profit education space.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $899M | $1.38B | $1.45B | $1.58B | $1.79B |
| Gross profit | — | — | — | — | — |
| Operating income | $110M | $76.7M | $168M | $217M | $342M |
| Net income | $70.0M | $311M | $93.4M | $137M | $237M |
| Diluted EPS | $1.36 | $6.43 | $2.05 | $3.39 | $6.18 |
| Net margin | 7.8% | 22.5% | 6.4% | 8.6% | 13.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.94B
EV / EBITDA—
EV / Sales2.8
EV / FCF17.2
P / FCF15.9
PEG (trailing)0.28
Earnings yield5.2%
FCF yield6.3%
Quality & risk
ROIC (est.)13.6%
Free cash flow$288M
Total debt$553M
Net cash-$353M
Altman Z-Score4.52 safe
Piotroski F-Score7/8
Capital returns
Buyback yield4.6%
Dividend yield (est.)0.0%
Shareholder yield4.6%
Shares Δ YoY-4.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Earnings results2026-05-07
Q3 FY26 results — continued enrollment-driven growth, lower debt service
- 10-Q Quarterly report2026-05-07
Q3 FY26 results — continued enrollment-driven growth, lower debt service
- 8-K Reg FD disclosure2026-04-09
Reg FD disclosure with exhibits — investor communication update
- 8-K Agreement terminated2026-03-03
Entered new material agreement and credit facility; prior agreement terminated
- 8-K Reg FD disclosure2026-02-24
Reg FD investor/conference update with supporting exhibits
- 8-K Charter / bylaws change2026-02-06
Bylaw/charter amendment filed alongside Reg FD disclosure
- 8-K Earnings results2026-01-28
Q2 FY26 quarterly results filed; momentum from FY25 trends extending
- 10-Q Quarterly report2026-01-28
Q2 FY26 quarterly results filed; momentum from FY25 trends extending
- 10-Q Quarterly report2025-10-30
Q1 FY26 results — first quarter after strong FY25, growth continuing
Recent filings
all on EDGAR ↗4Period ending 2026-06-102026-06-12open ↗144Filing2026-06-11open ↗144Filing2026-06-10open ↗11-KPeriod ending 2025-12-312026-06-01open ↗3Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-082026-05-12open ↗4Period ending 2026-05-082026-05-12open ↗4Period ending 2026-05-082026-05-12open ↗4Period ending 2026-05-082026-05-12open ↗144Filing2026-05-08open ↗144/AFiling2026-05-08open ↗
Frequently asked
- Is Covista Inc. (CVSA) a buy?
- CVSA currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Adtalem (CVSA) compounding nicely: 12.9% revenue growth, EPS +82%, deleveraging, and a buyback — still only 19.9x earnings.
- What is CVSA's fair value?
- A Modified-Graham model based on CVSA's SEC fundamentals estimates a fair value of about $234.84. It is an estimate from reported earnings, not a price target.
- Is CVSA overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, CVSA currently appears undervalued relative to its SEC-grounded earnings power.
- What is Covista Inc.'s quality score?
- CVSA scores 79.27450980392155/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000730464, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 12:58:05 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.